Interleukin-2-based immunotherapy in the management of minimal residual disease in acute leukemia patients.
Foa
R
R
Dipartimento di Scienze Biomediche e Oncologia Umana, University of Turin, Italy.
Meloni
G
G
Guarini
A
A
Vignetti
M
M
Marchis
D
D
Tosti
S
S
Gillio Tos
A
A
Mandelli
F
F
Gavosto
F
F
D000208:Acute Disease; D000818:Animals; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007938:Leukemia / Q000628:therapy*; D051379:Mice; D011994:Recombinant Proteins / Q000627:therapeutic use
D007376:Interleukin-2; D011994:Recombinant Proteins